Why Most CEAR Submissions Fail Before They Even Begin

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The Clinical Evaluation Assessment Report process is not a bureaucratic formality. It is a structured mechanism under MDR Article 61(2) that requires Notified Bodies to seek expert panel input when clinical evidence is insufficient to demonstrate conformity. The word “insufficient” carries weight here. It does not mean absent. It means the evidence exists but fails to adequately support the claims made for the device.

This distinction matters because manufacturers often misunderstand what triggers a CEAR. They assume it applies only to Class III devices with limited data. In reality, it applies whenever the Notified Body cannot confidently assess whether the clinical evaluation meets MDR Annex XIV requirements. That assessment begins long before the CEAR is drafted.

When Article 61 Gets Triggered

Article 61(2) is clear. If the clinical evaluation or its updates are not sufficient to demonstrate conformity with the relevant safety and performance requirements, the Notified Body shall seek the views of an expert panel. The term “not sufficient” is defined by what the clinical evaluation must demonstrate under Annex XIV: that the device achieves its intended performance, that the benefit-risk ratio is favorable, and that undesirable side effects are acceptable when weighed against the intended performance.

Here is where things break down. The Notified Body does not make this determination based on the CEAR alone. They make it based on the clinical evaluation report submitted as part of the technical documentation. If that report is weak, the CEAR process is triggered. If the CER is strong, the CEAR may never be needed.

Most deficiencies I see in CEAR submissions trace back to a clinical evaluation that was never built to withstand regulatory scrutiny. The device description is vague. The intended purpose is broad. The clinical claims lack specificity. The SOTA is outdated or incomplete. The equivalence demonstration is superficial. The clinical data appraisal lacks rigor.

When the Notified Body reviews this CER, they cannot reach a conclusion. They cannot determine whether the device meets the essential requirements. So they escalate to Article 61. The manufacturer then scrambles to prepare a CEAR based on a CER that was fundamentally flawed from the start.

What the CEAR Actually Contains

The CEAR is not a summary. It is not a condensed version of the clinical evaluation report. It is an assessment of why the available clinical evidence is insufficient and what additional data or analysis would be needed to reach a positive conclusion. This is a subtle but critical distinction.

The CEAR must include the device description, the intended purpose, the clinical claims, and the benefit-risk profile. It must also explain why the existing clinical data does not adequately support these claims. This requires the manufacturer to openly acknowledge gaps in their evidence base. That acknowledgment is uncomfortable but necessary.

The structure of the CEAR follows the logic of clinical evaluation under Annex XIV. It should address clinical performance, clinical safety, and the benefit-risk determination. It should reference the state of the art and explain where the device deviates or where the data diverges from established norms. It should identify which specific performance requirements or safety concerns remain inadequately supported.

The expert panel is not there to approve the device. They are there to advise the Notified Body on whether the clinical evidence, as presented, meets the threshold set by the MDR. If the CEAR hides gaps or overstates the strength of existing data, the panel will identify this immediately. The result is not just a negative opinion. It is a loss of credibility that extends beyond the specific device to the manufacturer’s entire quality system.

The Role of the Notified Body in Preparing the CEAR

Article 61(4) states that the Notified Body shall prepare a CEAR based on the clinical evaluation documentation provided by the manufacturer. This creates a dynamic that many manufacturers misunderstand. They assume the Notified Body will take their CER and simply repackage it for the expert panel. That is not what happens.

The Notified Body reviews the CER and identifies where the evidence falls short. They assess whether the clinical data supports the intended purpose, whether the SOTA analysis is comprehensive, whether the benefit-risk analysis is adequately justified. If they find gaps, they document these gaps in the CEAR. The manufacturer does not get to revise the CEAR before it goes to the panel. The Notified Body submits it as is.

This means the quality of the CER directly determines the content of the CEAR. If the CER is thorough, the CEAR will reflect that. If the CER is weak, the CEAR will expose every deficiency. Manufacturers who wait until the CEAR stage to address these deficiencies have already lost control of the process.

I have seen manufacturers submit CEARs—or rather, CERs that led to CEARs—without realizing the Notified Body would highlight unresolved safety concerns, inadequate clinical data, or unsupported benefit-risk conclusions. The manufacturer assumed these issues were minor. The Notified Body framed them as reasons the clinical evaluation was insufficient. The expert panel agreed.

What Happens After the CEAR Is Submitted

Once the Notified Body submits the CEAR to the expert panel, the manufacturer enters a waiting period. The panel reviews the CEAR, evaluates the clinical evidence, and issues a scientific opinion. That opinion is not binding, but it carries significant weight. If the panel concludes the clinical evidence is insufficient, the Notified Body will almost certainly require additional data or analysis before issuing a certificate.

The manufacturer may be invited to participate in the expert panel meeting or to provide additional information. This is not an opportunity to present new clinical data. It is an opportunity to clarify existing data, explain methodologies, or address specific questions raised by the panel. The panel’s role is to assess the adequacy of the clinical evaluation as it stands, not to help the manufacturer improve it.

What the panel looks for is consistency between the device claims, the clinical data, and the benefit-risk analysis. They assess whether the SOTA is accurately represented and whether the device’s performance and safety profile align with current medical knowledge. They consider whether the clinical investigation data, if any, is robust and whether the post-market surveillance plan adequately addresses residual uncertainties.

If the panel issues a negative opinion, the manufacturer must address the concerns raised before the Notified Body can proceed. This typically requires updating the CER, conducting additional clinical investigations, or revising the intended purpose or claims. The timeline extends. The costs increase. The regulatory pathway becomes uncertain.

How to Avoid the CEAR Process Altogether

The best way to manage the CEAR process is to avoid triggering it. That requires building a CER that leaves the Notified Body with no uncertainty about whether the device meets the essential requirements. This is harder than it sounds because it requires manufacturers to confront gaps in their evidence base early, before submission.

Start with a precise device description and intended purpose. Ambiguity creates uncertainty. Uncertainty triggers Article 61. The Notified Body must be able to understand exactly what the device does, for whom, and in what clinical context. If the intended purpose is broad, the evidence burden is proportionally broad. If the claims are vague, the Notified Body cannot assess whether the data supports them.

Next, conduct a rigorous SOTA analysis. The state of the art is not a literature review. It is a structured analysis of current medical knowledge, alternative treatments, and the clinical context in which the device will be used. The Notified Body uses the SOTA to assess whether your device represents an acceptable risk relative to current practice. If your SOTA is incomplete, they cannot make that assessment.

Then, ensure your clinical data directly supports your claims. Every claim in the intended purpose must be traceable to specific clinical evidence. If you claim the device reduces infection rates, you need data showing it reduces infection rates. If you claim it improves patient outcomes, you need outcome data. If you claim equivalence to another device, you need a structured equivalence demonstration that meets MDCG 2020-5 requirements.

Finally, be transparent about uncertainties and residual risks. The CER should acknowledge where data is limited and explain how post-market clinical follow-up will address those limitations. A transparent CER with a robust PMCF plan is more credible than one that overstates the strength of existing evidence.

The Strategic Implication

Article 61 is not a hurdle to be cleared. It is a signal that your clinical evaluation does not meet the threshold required by the MDR. The CEAR process gives you a second chance, but it also exposes your evidence strategy to external scrutiny. The expert panel will see what the Notified Body sees. If the foundation is weak, no amount of explanation will salvage it.

The manufacturers who succeed under MDR are those who treat clinical evaluation as a continuous process, not a document produced for submission. They invest in building a strong evidence base before they engage the Notified Body. They structure their CER to withstand scrutiny. They acknowledge gaps and address them proactively.

The manufacturers who struggle are those who treat clinical evaluation as a compliance exercise. They assemble data without a clear strategy. They write the CER to pass review, not to demonstrate conformity. When the Notified Body identifies insufficiencies, they are caught unprepared. The CEAR process becomes a reckoning rather than a consultation.

If your device is heading toward Article 61, ask yourself whether the issue is the device or the clinical evaluation. In most cases, it is the evaluation. And if the evaluation is insufficient, the CEAR will not fix it. Only a stronger CER will.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.